Fig. 6: Myeloid-specific deletion of LRP1 inhibits tumor growth by preventing the repression of Tsp-1.

A Plot of percentage of LRP1 + multiple myeloid and lymphoid cells in wild-type (n = 5) and LysM-Cre/LRP1^fl/fl (n = 5) mice as determined by FACS analysis. B Representative FACS plots of LRP1 expression in myeloid and lymphoid cells in wild-type and LysM-Cre/LRP1^fl/fl mice (n = 5 per group). C Plot of relative abundance of CD45 + myeloid and lymphoid cells in wild-type (n = 5) and LysM-Cre/LRP1^fl/fl (n = 5) mice as determined by FACS analysis. D Western blot of PRSS2 and Actin in Pan02 murine pancreatic cancer cells, SUM159 human breast cancer cells, and E0771 murine breast cancer cells (n = 3). E Plot of average tumor volume (as measured by calipers) of orthotopic mammary tumors formed by E0771 murine breast cancer cells in wild-type (red line), LysM-Cre/LRP1^fl/fl (green line), and LysM-Cre/LRP1^fl/fl/THBS1^−/− (blue) mice (n = 7 per group) (error bars depict SEM). F Dot plot of volume of tumors formed by E0771 cells in LysM-Cre/LRP1^fl/fl mice (LRP1mKO) (n = 7 mice per group). G Photographs of tumors formed by E0771 murine breast cancer cells in wild-type, LysM-Cre/LRP1^fl/fl, and LysM-Cre/LRP1^fl/fl/THBS1^−/− mice. H H&E and Tsp-1 immunohistochemical staining of tumors formed by E0771 murine breast cancer cells in wild-type, LysM-Cre/LRP1^fl/fl, and Tsp-1^−/−/LysM-Cre-LRP1^fl/fl mice (n = 7 mice per group) (scale bars = 100 μm).